Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 97 clinical trials
Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status

Beta blockers (BB) play an important role in protection of end organs that are susceptible for secondary injury by the Traumatic brain injury (TBI)-induced catecholamine surge. However, use of

  • 05 Mar, 2021
  • 1 location
Asian Diabetes Outcomes Prevention Trial

using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population

cardiovascular disease
heart failure
primary prevention
myocardial infarction
coronary revascularization
  • 23 Jan, 2021
  • 1 location
Safety Tolerability and Efficacy of Rapid Optimization Helped by NT-proBNP testinG of Heart Failure Therapies

STRONG-HF is a multicenter, randomized, parallel group study designed to evaluate the efficacy and safety of up-titration of standard oral heart failure medications during hospitalization for acute heart failure. Patients admitted for acute heart failure will be randomized within 2 days before discharge to either usual care or intensification of …

beta-adrenergic blocking agents
pulmonary congestion
  • 18 Feb, 2021
  • 158 locations
Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT

Myocardial infarction with non-obstructive coronary arteries" (MINOCA) occurs in 5-10% of all patients with AMI. There are neither any randomized clinical trials in MINOCA patients evaluating effects of secondary preventive treatments proven beneficial in patients with classic AMI, nor any treatment guidelines. The primary objective of this multi-national, multi-center pragmatic …

  • 25 Jan, 2021
  • 18 locations
FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction

Although current guidelines recommend fractional flow reserve (FFR) to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available (Class I, Level of Evidence: A), no published study has assessed the usefulness of FFR to guide percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) …

coronary artery disease
percutaneous coronary intervention
  • 23 Jan, 2021
  • 1 location
COlchicine in Cardiac Surgery

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine …

  • 24 Jan, 2021
  • 1 location
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it …

growth factor
heart failure
  • 05 Mar, 2021
  • 120 locations
Tranexamic Acid for Acute Upper Gastrointestinal Bleed in Cirrhosis

The management of acute upper gastrointestinal bleeding (UGIB) is challenging in patients with cirrhosis, as it is responsible for severe complications and high mortality rates. Fibrinolytic activity of the epithelial surfaces and of the submucosal blood vessels may interfere with hematemesis and even delay healing of ulcers. Tranexamic acid (TXA) …

  • 26 Jan, 2021
  • 1 location
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of death from any cause, recurrent MI, unstable angina pectoris, stroke or heart failure.

heart failure
unstable angina
ejection fraction
beta blocker
  • 23 Jan, 2021
  • 1 location
Beta Blocker Interruption After Uncomplicated Myocardial Infarction

ABYSS is a national, multicenter, randomised, open label trial using the PROBE study design, that will evaluate the non-inferiority of the interruption of B therapy after an uncomplicated MI after six months or more of follow-up compared to the continuation of B evaluated by the primary endpoint or death, MI, …

myocardial infarction
acute myocardial infarction
q waves
  • 26 Jan, 2021
  • 1 location